Login / Signup

Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.

Olivier CussenotRaphaele Renard-PennaSarah MontagneValerie OndetAntoine PilonJerome GuechotEva ComperatFreddie HamdyAlastair D LambGeraldine Cancel-Tassin
Published in: BJU international (2023)
We found that screening men at high genetic risk of PCa must be based on mpMRI without pre-screening based on a PSA level of >3 ng/mL, to avoid missing too many ISUP grade >1 tumours and to significantly reduce the number of unnecessary biopsies. However, urinary markers or a PSAD of ≥0.10 ng/mL/mL when mpMRI was negative increased the detection of ISUP grade >1 cancers. We suggest that a baseline mpMRI be discussed for men at high genetic risk from the age of 40 years.
Keyphrases
  • prostate cancer
  • magnetic resonance imaging
  • genome wide
  • radical prostatectomy
  • middle aged
  • copy number
  • computed tomography
  • magnetic resonance
  • contrast enhanced